Can we cure head and neck cancer with less treatment?
For decades, treating head and neck cancer has often meant accepting a difficult trade-off: treatments may cure the cancer, but surgery, chemotherapy and radiotherapy can leave people with significant and sometimes lifelong effects.
Now researchers are asking an important question:
For some patients, can we achieve the same chance of cure while giving less treatment?
This approach is known as treatment de-intensification.
It does not mean simply reducing treatment. Instead, doctors are trying to identify particular patients whose cancer biology, response to treatment and other characteristics suggest that they can safely receive less intensive therapy.
Why does this matter so much in head and neck cancer?
Treatment can affect some of the most basic things we do every day: eating, swallowing, speaking, hearing and communicating.
Radiotherapy can also cause long-term dry mouth, swallowing difficulties and damage to the jawbone, while chemotherapy and surgery bring their own significant side effects.
For people who may live for decades after treatment—particularly the growing number of younger people diagnosed with HPV-related oropharyngeal cancer—reducing these lifelong effects could make an enormous difference.
The goal is therefore becoming more ambitious:
Not simply curing the cancer, but curing it while preserving as much function and quality of life as possible.
How could treatment be reduced?
Researchers are investigating several different approaches.
One is transoral robotic surgery (TORS), which allows surgeons to reach some tumours at the back of the throat through the mouth.
Because surgeons can remove and examine the tumour precisely, the pathology may help determine whether a patient really needs chemotherapy or radiotherapy afterwards. In selected cases, Cleveland Clinic reports that some patients have been able to avoid these treatments altogether.
Another approach is reducing the amount of radiotherapy given to healthy tissues.
Cleveland Clinic describes reducing elective radiation doses in some situations from 56 Gy to 30 Gy, substantially decreasing radiation exposure to structures involved in swallowing and speech.
Doctors are also experimenting with response-adapted treatment. Patients may first receive chemotherapy or immunotherapy, and their subsequent radiotherapy can then be adjusted according to how well their cancer responds.
Could some patients receive dramatically less radiation?
One particularly interesting study is called 30-ROC.
Researchers investigated people with HPV-related oropharyngeal cancer and used information about the amount of oxygen within their tumours to help guide treatment.
Tumours with good oxygenation may be more sensitive to radiotherapy.
Around 80% of patients in the study were able to receive just 30 Gy of radiation rather than the standard 70 Gy, with impressive cancer control and substantially reduced toxicity.
Patients whose tumours showed signs of low oxygen levels continued to receive the standard 70 Gy treatment.
These findings are now being tested in a Phase III clinical trial.
This is an important distinction: researchers aren't simply deciding that everyone needs less radiation. They are trying to develop ways of identifying which individual cancers can safely be treated with less.
Blood tests may eventually help guide these decisions
Another exciting development is the increasing use of circulating tumour DNA (ctDNA).
Tiny fragments of DNA released by cancer cells can sometimes be detected in a person's blood.
In HPV-related head and neck cancer, circulating HPV DNA can be monitored during treatment and may provide additional information about how well the cancer is responding.
Researchers are investigating whether these kinds of blood tests could eventually help doctors decide whether an individual patient needs more treatment—or whether some treatment can safely be avoided.
Proton therapy may also reduce treatment burden
De-intensification isn't necessarily just about lowering the radiation dose.
It can also mean delivering treatment in a way that exposes less healthy tissue to radiation.
The article highlights a Phase III trial showing that intensity-modulated proton therapy reduced feeding-tube use compared with conventional intensity-modulated photon radiotherapy.
For head and neck cancer patients, where maintaining swallowing function is so important, that is a meaningful outcome.
But there is a very important warning
Giving less treatment is only worthwhile if it doesn't reduce the chance of curing the cancer.
And unfortunately, some previous attempts at de-intensifying head and neck cancer treatment have failed because cancer outcomes were worse.
That is why this research has to proceed cautiously.
As radiation oncologist Dr Shlomo Koyfman explains, reducing treatment only to increase the chance of the cancer returning would be a very poor trade-off, particularly because treating recurrent disease successfully can be much more difficult.
So who might receive less treatment?
Increasingly, the answer may come from combining many different pieces of information.
Doctors may consider:
HPV status and tumour biology
advanced imaging
tumour genetics
circulating tumour DNA
oxygen levels within the tumour
pathology following surgery
how well the cancer responds to initial treatment.
Instead of every person with a particular stage of cancer automatically receiving essentially the same treatment, the future may involve treatment becoming much more individualised.
Some cancers will still require very aggressive treatment.
Others may not.
The challenge is learning how to reliably tell the difference.
What does this mean for our community?
This research represents an important change in the way we think about progress in head and neck cancer.
For many years, success was understandably measured primarily by whether treatment controlled or cured the cancer.
That must remain the first priority.
But for people who survive head and neck cancer, what life is like after treatment matters enormously too.
Being able to swallow. Being able to eat. Being able to speak and communicate. Maintaining dental and jaw health. Avoiding a feeding tube where possible. And reducing the long-term effects that can continue for years or decades after treatment.
The future of head and neck cancer treatment may therefore not always involve more treatment.
For carefully selected patients, progress may mean less treatment—but much more precisely chosen treatment.
The takeaway: Researchers are increasingly investigating whether some people with head and neck cancer—particularly certain HPV-positive oropharyngeal cancers—can safely receive less surgery, chemotherapy or radiotherapy without compromising their chance of cure. Early results from several approaches are encouraging, but de-intensification is not appropriate for everyone and must be carefully tested. The ultimate goal is simple but enormously important: cure the cancer while leaving people with the best possible quality of life afterwards.
